作者
Daniela Puzzo, Walter Gulisano, Agostino Palmeri, Ottavio Arancio
发表日期
2015/7/3
来源
Expert opinion on drug discovery
卷号
10
期号
7
页码范围
703-711
出版商
Informa Healthcare
简介
Introduction: Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by memory loss and personality changes, leading to dementia. Histopathological hallmarks are represented by aggregates of beta-amyloid peptide (Aβ) in senile plaques and deposition of hyperphosphorylated tau protein in neurofibrillary tangles in the brain. Rare forms of early onset familial Alzheimer’s disease are due to gene mutations. This has prompted researchers to develop genetically modified animals that could recapitulate the main features of the disease. The use of these models is complemented by non-genetically modified animals.
Areas covered: This review summarizes the characteristics of the most used transgenic (Tg) and non-Tg models of AD. The authors have focused on models mainly used in their laboratories including amyloid precursor protein (APP) Tg2576, APP/presenilin 1, 3xAD, single h-Tau, non-Tg …
引用总数
2015201620172018201920202021202220232024117363530193123309
学术搜索中的文章
D Puzzo, W Gulisano, A Palmeri, O Arancio - Expert opinion on drug discovery, 2015